These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 30682180)
41. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413 [TBL] [Abstract][Full Text] [Related]
42. CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR. Saracino A; Bruno G; Scudeller L; Ladisa N; de Gennaro N; Allegrini M; Monno L; Angarano G J Clin Virol; 2016 Aug; 81():94-9. PubMed ID: 27371888 [TBL] [Abstract][Full Text] [Related]
43. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
44. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response. Casado JL; Esteban MA; Bañón S; Moreno A; Perez-Elías MJ; Mateos ML; Moreno S; Quereda C Dig Dis Sci; 2015 Nov; 60(11):3473-81. PubMed ID: 26112991 [TBL] [Abstract][Full Text] [Related]
45. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Young J; Rossi C; Gill J; Walmsley S; Cooper C; Cox J; Martel-Laferriere V; Conway B; Pick N; Vachon ML; Klein MB; Clin Infect Dis; 2017 May; 64(9):1154-1162. PubMed ID: 28199495 [TBL] [Abstract][Full Text] [Related]
46. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. Chen Yi Mei SLG; Thompson AJ; Christensen B; Cunningham G; McDonald L; Bell S; Iser D; Nguyen T; Desmond PV PLoS One; 2017; 12(10):e0185609. PubMed ID: 29065124 [TBL] [Abstract][Full Text] [Related]
47. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513 [TBL] [Abstract][Full Text] [Related]
48. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F; J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903 [TBL] [Abstract][Full Text] [Related]
49. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546 [TBL] [Abstract][Full Text] [Related]
50. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. Yeung MW; Young J; Moodie E; Rollet-Kurhajec KC; Schwartzman K; Greenaway C; Cooper C; Cox J; Gill J; Hull M; Walmsley S; Klein MB HIV Clin Trials; 2015; 16(3):100-10. PubMed ID: 25972048 [TBL] [Abstract][Full Text] [Related]
51. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. Kronfli N; Bhatnagar SR; Hull MW; Moodie EEM; Cox J; Walmsley S; Gill J; Cooper C; Martel-Laferrière V; Pick N; Klein MB; AIDS; 2019 May; 33(6):1013-1022. PubMed ID: 30946155 [TBL] [Abstract][Full Text] [Related]
52. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP; PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764 [TBL] [Abstract][Full Text] [Related]
53. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452 [TBL] [Abstract][Full Text] [Related]
54. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. Berenguer J; Alvarez-Pellicer J; Carrero A; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Tural C; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Barquilla E; Bellón JM; González-García J; J Hepatol; 2013 Jun; 58(6):1104-12. PubMed ID: 23395690 [TBL] [Abstract][Full Text] [Related]
55. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517 [TBL] [Abstract][Full Text] [Related]
56. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Singh S; Facciorusso A; Loomba R; Falck-Ytter YT Clin Gastroenterol Hepatol; 2018 Jan; 16(1):27-38.e4. PubMed ID: 28479504 [TBL] [Abstract][Full Text] [Related]
57. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):351-8. PubMed ID: 24580042 [TBL] [Abstract][Full Text] [Related]
58. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. Márquez-Coello M; Arizcorreta A; Rodríguez-Pardo M; Illanes-Álvarez F; Márquez D; Cuesta-Sancho S; Girón-González JA Sci Rep; 2021 May; 11(1):9824. PubMed ID: 33972651 [TBL] [Abstract][Full Text] [Related]
59. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J; PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696 [TBL] [Abstract][Full Text] [Related]
60. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort). Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP; Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]